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Abstract
With the growing use of low-molecular-weight heparins (LMWH) for the treatment and
prevention of venous thromboembolism (VTE), it is important to provide an evidence-based
comparison with unfractionated heparin (UFH) concerning rates of heparin-induced
thrombocytopenia (HIT). Such comparisons are essential in clinical decision-making and cost-
modeling. In this paper we review data regarding non-surgical (medical) patients. We conclude that
the lack of uniform evaluation and standardized testing for HIT in the current literature precludes
making a reliable estimate of the relative risk of HIT in UFH vs. LMWH in either the treatment or
prevention of VTE in non-surgical patients. However, current data suggest that the risk of
thrombocytopenia and HIT is low and similar for non-surgical patients who receive either LMWH
or UFH.
Heparin-induced thrombocytopenia (HIT) is recognized
as a rare, but potentially devastating complication of
heparin therapy because of its association with arterial
and venous thrombosis [1]. HIT is mediated by antibod-
ies which recognize an antigen formed by the binding of
platelet factor 4 to heparin [2]. The now widespread use of
low-molecular-weight heparins for a variety of indications
previously reserved exclusively for unfractionated heparin
has generated interest in comparing the relative rates of
HIT between the two classes of heparin.
In 1995 Warkentin examined rates of HIT in patients
undergoing elective hip arthroplasty who had been rand-
omized to receive either unfractionated heparin (UFH) or
low molecular weight heparin (LMWH) for thrombo-
prophylaxis [3]. Warkentin reported that HIT occurred in
9 of 332 patients who received UFH and in none of 333
patients who received LMWH (2.7 percent vs. 0 percent).
In addition, development of heparin-dependent IgG anti-
bodies and thrombotic events associated with thrombocy-
topenia were more common in patients treated with UFH
than in those treated with LMWH.
Recently, using different criteria for HIT (an absolute drop
in platelet count of 50% or greater vs. platelet count less
than 150,000 cells /ml), Warkentin reanalyzed these same
data and found the difference in the observed rate of HIT
was even more pronounced, 8 times greater (4.8% vs.
0.6%) in UFH compared to LMWH for prophylaxis of
venous thromboembolism (VTE) in patients undergoing
elective hip arthroplasty [4].
Warkentin's results are supported by a recent study by
Walenga et al which carefully evaluated sera from three
Published: 04 April 2005
Thrombosis Journal 2005, 3:4 doi:10.1186/1477-9560-3-4
Received: 29 September 2004
Accepted: 04 April 2005
This article is available from: http://www.thrombosisjournal.com/content/3/1/4
© 2005 Locke et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Thrombosis Journal 2005, 3:4 http://www.thrombosisjournal.com/content/3/1/4
Page 2 of 5
(page number not for citation purposes)
clinical studies [5]. Walenga found that LMWH was less
likely to generate H-PF4 antibodies than UFH and less
likely to result in clinical HIT. Walenga also noted that
LMWH were more likely to generate IgA and IgM antibod-
ies rather than IgG antibodies, which are associated with
clinical HIT. However, the sera reviewed by Walenga all
were from orthopedic surgical patients.
Authors in the medical literature often generalize Wark-
entin's results, applying them to medical as well as surgi-
cal patients [6-8]. Further, it has been suggested that
differences in rates of HIT represent an advantage of
LMWH over UFH in VTE prophylaxis in non-surgical
patients [7,9].
However, we do not think the Warkentin data can be
applied with confidence to non-surgical patient popula-
tions. In non-surgical (medical) patients, the rate of HIT
with UFH is reported to be much lower than in Wark-
entin's analysis of surgical patients. For example, an ear-
lier study cited in Warkentin's 1995 paper reported an
incidence of HIT of only 0.3% for non-surgical patients
who received therapeutic intravenous UFH [10].
Table 1: Treatment duration and reported adverse event rates in studies comparing UFH vs. LMWH heparin in the treatment and 
prophylaxis of VTE
Treatment of VTE
Study Treatment duration (days) Reported 
Adverse 
Event
UFH LMWH
UFH LMWH % n/N % n/N
Merli [11] ≥  5‡ ≥  5‡ T* 1.4 4/290 2.0 12/610
Koopman [12] 6.1 6.5 T(u) 2.5 5/198 1.5 3/202
Levine [13] 5.5 5.8 T 1.9 3/253 2.0 5/247
T w/o exp. 0.4 1/253 0.4 1/247
Hull [14] not stated T(u) 1.0 1/103 3.1 3/97
Columbus Invest [15] 5.8 6.3 HIT 0.3 1/308 0.0 0/304
Simmoneau [16] 7.0 7.3 HIT 0.3 1/308 0.0 0/304
Prophylaxis of VTE
Study Treatment duration (days) Reported 
Adverse 
Event
UFH LMWH
UFH LMWH % n/N % n/N
Harenberg, 1990 [17] 10 10 ** -/82 -/84
Harenberg, 1996 [18] 10 10 T(d) 0.5 4/780 0.0 0/810
PRIME [19] 7 7 T (n) 0.0 0/482 0.0 0/477
Bergmann [20] 10 10 HIT† 0.4 1/223 0.0 0/216
PRINCE [21] 10 10 T NR NR
Key:
T:Thrombocytopenia, defined as platelet count less than 100,000 cells/ml,
*One case of "immune thrombocytopenia reported in this study". Case was in the LMWH group but had received UFH prior to randomization.
T(u) – Thrombocytopenia-undefined in study
T w/o exp. – Thrombocytopenia with "no apparent explanation"
NR: not reported,
**: "Thrombocyte count did not change in either group".
T(d): A decrease in platelet count (values ranging between 40,000 and 80,000/microliter) was observed in four patients with UF and in none with 
LMW heparin. No severe thrombocytopenia was observed.
T(n): "There was no decrease in platelet count due to enoxaparin or Ca-heparin."
† One patient with drop in platelet count from 149 K cells/ml to 87 K during treatment. Platelet count rose to 280 K post study. No sequallae from 
thrombocytopenia.
‡ Average length of treatment not stated. Treatment length "at least five days".Thrombosis Journal 2005, 3:4 http://www.thrombosisjournal.com/content/3/1/4
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To evaluate the relative rates of HIT in non-surgical
patients we reviewed recent studies that compared UFH to
LMWH in either the treatment or prevention of VTE in
medical (non-surgical) patients. We chose studies availa-
ble to us through PubMed. In our review, we found 11 tri-
als that reported either HIT (which, as Warkentin points
out, does not have a uniform definition), thrombocytope-
nia, "severe thrombocytopenia" or some combination of
the above. Our findings are listed in the table 1.
The studies cited in the tables are heterogeneous in the
endpoints used. Given the variability in definition of
thrombocytopenia among the trials and the lack of stand-
ardized and routine evaluation for HIT in any of the above
studies we feel it is currently impossible to estimate the
relative risk of HIT in UFH vs. LMWH in either the treat-
ment of VTE or prevention of VTE in non-surgical
patients. However, the data do suggest that thrombocyto-
penia is rather uncommon with either heparin therapy.
Insofar as the rate of HIT must be less than that of throm-
bocytopenia, HIT is likely to be an infrequent event as
well.
A recently published study provided a rigorous analysis of
H-PF4 antibodies in patients treated for deep vein throm-
bosis with LMWH vs. UFH [22]. In this study, H-PF4 anti-
bodies (measured by a commercial ELISA method)
developed in 9.1% of patents in the UFH group vs. 2.8%
of patients in the LMWH group (both treated for 5–7
days). However, there was only one occurrence of HIT
with thrombosis among 356 patients in the UFH group vs.
no occurrences of HIT among 374 patients in the LMWH
group. This study, we feel, is consistent with both Wark-
entin's data regarding orthopedic surgery patients and the
data presented in our table above; namely, LMWH
induces H-PF4 antibodies at a lower rate than UFH but
that clinical incidence of HIT in non-surgical patients is
too small to statistically differentiate.
Unfortunately, the generalization to medical patients of
Warkentin's data regarding HIT rates for orthopedic surgi-
cal patients persists in the literature. As recently as 2004, a
meta-analysis comparing heparins for the treatment of
pulmonary embolism cited "the lower risk for...heparin-
induced thrombocytopenia" as an advantage of LMWH
over UFH [7]. As justification, this paper references a
review article [8] which in turn, references the 1995 Wark-
entin paper [3] which, as discussed above, involved exclu-
sively orthopedic surgical patients.
One possible explanation as to why the studies of treat-
ment and prevention of VTE in medical patients have not
demonstrated a difference in thrombocytopenia or HIT
rates is because the length of treatment in these studies
may be too short for patients to develop HIT. In a study
which clearly demonstrated a difference in HIT rates for
LMWH vs. UFH following cardiopulmonary bypass sur-
gery, 4 patients developed significant levels of Heparin-
PF4 antibodies in days 3–5 postoperatively vs. 75 patients
in days 7–10 post operatively [23]. Similarly, in Wark-
entin's data, thrombocytopenia typically developed 6–13
days after surgery (and of heparin therapy) and throm-
botic events occurred 7–17 days after surgery [3].
In a recent study, Girolami et al reviewed 598 consecutive
patients admitted to a medical ward with either a thera-
peutic or prophylactic indication for UFH [24]. HIT was
not observed in any of the 238 patients who received UFH
for a therapeutic indication. The authors speculate that
HIT was not observed in these patients because duration
of heparin was less than one week. There were 5 cases of
HIT observed in the 598 patients (0.8%), all in those
patients who received heparin for prophylactic indication.
These cases occurred from day 8 to day 22 of therapy and
the three observed associated thrombotic events occurred
on days 10–21 of therapy. Such data are consistent with
the College of American Pathologists (CAP) 2002 recom-
mendations that platelet monitoring for HIT should focus
on days 4–10 after starting heparin [25]. In addition, the
CAP position on monitoring for HIT differentiates medi-
cal vs. surgical patients, with more frequent platelet count
monitoring recommended for surgical patients. The CAP
calls "postoperative" patients receiving UFH at "highest"
risk for HIT, while "medical" patients receiving UFH are
considered at "intermediate" risk [25].
The Girolami study further support the position that, in
most cases, the use of heparin for the treatment of VTE is
limited to the first 5–7 days of treatment and that heparin
(either LMWH or UFH) is discontinued before clinical
HIT, as evidenced by either thrombocytopenia and/or
thrombosis, generally occurs. Similarly, the strong corre-
spondence of length-of-treatment with the likelihood of
development of H-PF4 antibodies and HIT is likely
important in prophylaxis of non-surgical patients as well.
In the studies we reviewed, the length of heparin pharma-
coprophylaxis was generally 7–10 days. Despite this
length of treatment being ostensibly long enough for
patients to develop laboratory-evident HIT we suggest that
7–10 days of therapy is too short of a duration for many
cases of potential clinically-evident HIT to manifest. This
could limit the potential clinical import of differences in
rates of HIT for UFH and LMWH. Indeed, our experience
is that length-of-stay in our institution for most of our
medical patients eligible for pharmacoprophylaxis is 10
days or less. Additionally, in the studies of "medical
patients" we reviewed, the risk low and similar risk of
either thrombocytopenia, HIT or thrombotic complica-
tions of HIT in the UFH and LMWH groups may also be,Thrombosis Journal 2005, 3:4 http://www.thrombosisjournal.com/content/3/1/4
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in part, due to the absence of surgical activation of PF-4 in
these patients.
Accurate assessment of the risks and benefits of competing
therapies is paramount to sound cost-effective decision-
making. At our institution, acquisition costs for branded
LMWH are approximately 15 times that of generic UFH, a
factor that would certainly favor the latter if efficacy and
safety are similar. In Europe and Canada, where cost dif-
ferences between LMWH and UFH are less pronounced,
clinical decision-making and cost-modeling may be dif-
ferent than in the United States. Indeed, the latest Amer-
cian College of Chest Physicians' (ACCP) guidelines on
antithrombotic therapy recognize that "the cost for low-
molecular-weight heparin (LMWH) is high in the United
States, but low in most European countries. Thus, in
instances in which small benefits accrue to patients from
the use of LMWH in comparison to the use of unfraction-
ated heparin, the choice in favor of LMWH may be clear
in Europe, but much less clear in North America" [26].
However, given the serious (and expensive) nature of
complications from HIT, true differences in clinical HIT
with thrombosis between UFH and LMWH would affect
significantly safety considerations as well as total health
care cost-modeling between the two therapies. Unfortu-
nately, we feel sufficient information in this area are cur-
rently lacking.
We encourage investigators to make a rigorous evaluation
of HIT using new definitions proposed by Dr. Warkentin
in his 2003 paper [4] as part of any future studies compar-
ing LMWH and UFH for either the treatment or preven-
tion of VTE in non-surgical patients to better define the
risk of this important clinical problem.
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